Zinc Finger Proteins Modulate Trinucleotide Repeat Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for trinucleotide repeat disorders, such as Huntington's disease, are limited in effectiveness, with no statistically significant improvements in neuron function observed in clinical trials, highlighting the need for new compositions and methods to modulate gene expression and treat these disorders.
Innovation Solution
Engineered zinc finger proteins (ZFPs) are developed to specifically bind to and modulate trinucleotide repeat sequences, including those in the Huntingtin (Htt) gene, allowing for the repression or activation of mutant and wild-type alleles, and are used in conjunction with neurotrophic factors like BDNF and GDNF to treat trinucleotide repeat disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for trinucleotide repeat disorders are used, then disease progression is addressed, but no statistically significant improvements in neuron function are observed
Solution Approach 1:
The patent introduces zinc finger proteins as intermediary molecules that specifically bind to trinucleotide repeat sequences. These ZFPs act as mediators between the therapeutic approach and the mutant genes, enabling targeted modulation of gene expression without directly affecting neuronal function, thus resolving the contradiction between treatment application and functional improvement
Solution Approach 2:
The patent employs parameter changes by modifying gene expression levels through ZFP-mediated mechanisms. By changing the expression parameters of mutant alleles (repression) or neurotrophic factors (activation), the treatment achieves significant improvements in neuron function that were not attainable with current therapies
2Measurement precision
If engineered zinc finger proteins are used to specifically target mutant alleles, then gene expression modulation is achieved, but treatment complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the treatment into distinct functional modules: ZFPs for specific mutant allele recognition and binding, repression domains for selective gene silencing, and separate activation components for neurotrophic factor induction. This modular segmentation achieves high targeting specificity while managing treatment complexity through functional decomposition
Solution Approach 2:
The patent employs universality by designing zinc finger protein modules that can be configured with different functional domains (repression, activation, or both). This multi-functional design allows a single ZFP platform to address multiple therapeutic needs—mutant allele suppression and neurotrophic factor induction—thereby reducing overall treatment complexity while maintaining high specificity
3Manufacturing precision
If zinc finger proteins are designed to bind expanded trinucleotide repeats, then mutant allele repression is achieved, but wild-type allele expression may be affected
Solution Approach 1:
The patent applies local quality by designing zinc finger proteins with customized DNA-binding specificities that match the local sequence context of expanded trinucleotide repeats. The ZFPs are engineered to recognize specific flanking sequences adjacent to the expansion, enabling discrimination between mutant and wild-type alleles based on local sequence differences rather than just the repeat length
Solution Approach 2:
The patent employs dynamics by creating zinc finger proteins with adjustable binding affinities that can be tuned to preferentially bind expanded repeats over wild-type sequences. The modular nature of ZFPs allows optimization of binding strength and specificity through selection and engineering, enabling dynamic adjustment of allele discrimination accuracy while maintaining high manufacturing precision for repeat sequence binding
Data Source
AI summary
Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.